Applied DNA Sciences Acquires License for Molecular Beacons Technology
08 February 2007 - 11:30PM
PR Newswire (US)
STONY BROOK, N.Y., Feb. 8 /PRNewswire-FirstCall/ -- Applied DNA
Sciences, Inc. (OTC:APDN) (BULLETIN BOARD: APDN) , a DNA security
solutions company, today announced that it has in-licensed the
rights to PHRI Properties molecular beacons technology. Applied DNA
Sciences plans to incorporate the molecular beacons in its next
generation instant detection devices. These products will
complement the existing detection methods being utilized by Applied
DNA Sciences and its customers and will offer another method for
quick on-site verification of customers' products. APDN's
SigNature(TM) Program consists of three steps: creating and
encapsulating a specific encrypted DNA segment, applying it to a
product or other item, and detecting the presence or absence of the
specific agent. Once applied, the presence of any of our
SigNature(TM) DNA Markers can be detected by APDN or a customer in
a simple spot test. The instant detection device being developed
using the molecular beacons technology, will provide an alternate
simple, instant on-site authentication test which can detect
SigNature(TM) DNA Markers in a range of different media, including
but not limited to ink, thread, and adhesives. For forensic
authentication, a sample taken from the product or other item can
be analyzed using our proprietary primers and PCR technology to
obtain definitive proof of the presence or absence of a
SigNature(TM) DNA Marker. Dr. James A. Hayward, CEO of Applied DNA
Sciences stated, "We are pleased with the addition of this exciting
technology to our portfolio. This license is another step forward
in the continued development and enhancement of our SigNature(TM)
Program. APDN is constantly working to develop new, faster and more
convenient detection technologies, to strengthen its business and
to enhance APDN's ability to detect counterfeit goods and products,
which could help make the world a safer place." About PHRI and
UMDNJ The Public Health Research Institute Center (PHRI), an
independent, not-for-profit research organization, was founded in
1941 in New York City. PHRI moved to Newark in 2002 to join the
International Center for Public Health, an infectious disease
consortium comprised of the Department of Microbiology and
Molecular Genetics and The Global TB Institute at the UMDNJ- New
Jersey Medical School and the UMDNJ-School of Public Health. In
December of 2006, PHRI was officially incorporated into the
UMDNJ-New Jersey Medical School. The University of Medicine and
Dentistry of New Jersey (UMDNJ) is the nation's largest
free-standing public health sciences university with more than
5,500 students attending the state's three medical schools, its
only dental school, a graduate school of biomedical sciences, a
school of health- related professions, a school of nursing and its
only school of public health. UMDNJ has campuses in Newark, New
Brunswick/Piscataway, Scotch Plains, Camden and Stratford. About
Applied DNA Sciences, Inc. Applied DNA Sciences, Inc. provides
botanical DNA encryption, embedment and authentication solutions
that can help protect companies, governments and consumers from
counterfeiting, fraud, piracy, product diversion, identity theft
and unauthorized intrusion into physical locations and databases.
APDN's common stock is listed on the Over-The-Counter Bulletin
Board under the symbol "APDN". Contact: Debbie Bailey, Applied DNA
Sciences, Inc., 25 Health Sciences Drive, Stony Brook, New York
11790; Tel: 631-444-8090; Fax: 631-444-8848 http://www.adnas.com/.
The statements made by APDN may be forward-looking in nature and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements describe APDN's future plans, projections, strategies
and expectations, and are based on assumptions and involve a number
of risks and uncertainties, many of which are beyond the control of
APDN. Actual results could differ materially from those projected
due to our short operating history, limited market acceptance,
market competition and various other factors detailed from time to
time in APDN's SEC reports and filings, including our Registration
Statement on Form SB-2 as amended, and Annual Report on Form
10-KSB, filed on January 16, 2007. APDN undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to
reflect the occurrence of unanticipated events. DATASOURCE: Applied
DNA Sciences, Inc. CONTACT: Debbie Bailey, +1-631-444-8090, or fax:
+1-631-444-8848, for Applied DNA Sciences, Inc. Web site:
http://www.adnas.com/
Copyright